MacroGenics Inc - Asset Resilience Ratio
MacroGenics Inc (MGNX) has an Asset Resilience Ratio of 51.66% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does MacroGenics Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2025)
This chart shows how MacroGenics Inc's Asset Resilience Ratio has changed over time. See MGNX book value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MacroGenics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MGNX company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $132.70 Million | 51.66% |
| Total Liquid Assets | $132.70 Million | 51.66% |
Asset Resilience Insights
- Very High Liquidity: MacroGenics Inc maintains exceptional liquid asset reserves at 51.66% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
MacroGenics Inc Industry Peers by Asset Resilience Ratio
Compare MacroGenics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for MacroGenics Inc (2013–2025)
The table below shows the annual Asset Resilience Ratio data for MacroGenics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 51.66% | $132.70 Million | $256.85 Million | +44.47pp |
| 2024-12-31 | 7.20% | $18.83 Million | $261.65 Million | -35.98pp |
| 2023-12-31 | 43.18% | $128.85 Million | $298.42 Million | +27.47pp |
| 2022-12-31 | 15.70% | $45.46 Million | $289.51 Million | -20.14pp |
| 2021-12-31 | 35.84% | $120.15 Million | $335.25 Million | +11.71pp |
| 2020-12-31 | 24.13% | $91.40 Million | $378.74 Million | -4.44pp |
| 2019-12-31 | 28.57% | $89.28 Million | $312.50 Million | +24.74pp |
| 2018-12-31 | 3.83% | $12.73 Million | $332.13 Million | -21.15pp |
| 2017-12-31 | 24.98% | $93.39 Million | $373.88 Million | -36.99pp |
| 2016-12-31 | 61.97% | $192.90 Million | $311.26 Million | +22.20pp |
| 2015-12-31 | 39.77% | $142.88 Million | $359.27 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $173.89 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $125.78 Million | -- |
About MacroGenics Inc
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical tri… Read more